Advanced CSCC expert video library

Explore this video library featuring medical experts to learn more about LIBTAYO for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Watch videos discussing various topics including the efficacy and safety profile of LIBTAYO, clinical trial designs, and patient case studies.

Indications and Usage

LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.